<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="reducing SARS-CoV-2 viral replication. He received a 1-week course of" exact="prednisolone" post="and valacyclovir for treatment of facial palsy. Upon review"/>
 <result pre="viral replication. He received a 1-week course of prednisolone and" exact="valacyclovir" post="for treatment of facial palsy. Upon review 1â€‰week later,"/>
 <result pre="prompt treatment re-initiation is particularly important in the cases of" exact="fingolimod" post="and natalizumab, in order to minimize the risk of"/>
 <result pre="that may be tested and used against SARS-CoV-2. For example," exact="hydroxychloroquine" post="sulphate has been associated with headache, dizziness and extrapyramidal"/>
 <result pre="when patients with disorders of the neuromuscular junction are prescribed" exact="hydroxychloroquine" post="sulphate, especially with co-administration of aminoglycoside antibiotics. Certain drug"/>
 <result pre="aminoglycoside antibiotics. Certain drug databases report additional minor interactions of" exact="chloroquine" post="with anti-Xa inhibitors, resulting in a decrease of their"/>
 <result pre="All direct oral anticoagulants also interact with the antiviral agent" exact="ritonavir" post="(a protease inhibitor used in conjunction with another PI"/>
</results>
